Cox Communications 주식 가격. COX - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

개인 투자자를 위한 전문가급 도구.

프리미엄

가격

매수가

매도가

거래량

0.00 일간 변동폭 0.00

0.00 52주 범위 0.00

전일 종가

개장가

최근 거래 시간

마지막 거래 시간

평균 볼륨(3m)

재정 규모

VWAP

Nicox first quarter 2015 financial and business update

SOPHIA ANTIPOLIS, France, April 17, 2015 (GLOBE NEWSWIRE) -- Nicox S.A. (Euronext Paris: FR0000074130, COX), the international ophthalmic company, today reported its first quarter 2015 revenues...

Nicox 2014 Financial Results and Business Update

A year of strategic progress: Positive phase 3 results for Vesneo(TM) (Bausch + Lomb); NDA submission on track for Q2 2015 Significant strengthening of ophthalmic therapeutics...

Nicox receives Orphan Drug Designation from FDA for naproxcinod in Duchenne Muscular Dystrophy

SOPHIA ANTIPOLIS, France, March 19, 2015 (GLOBE NEWSWIRE) -- Nicox S.A. (Euronext Paris: COX) today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug...

Nicox signs exclusive license agreement with InSite Vision for AzaSite(R) and BromSite(TM) in Europe

InSite grants Nicox exclusive license for AzaSite® (1% azithromycin), BromSite(TM) (0.075% bromfenac) and AzaSite Xtra(TM) (2% azithromycin) in Europe, Middle East and...

Nicox holds successful pre-NDA meeting with FDA on AC-170 clinical package

SOPHIA ANTIPOLIS, France, Jan. 26, 2015 (GLOBE NEWSWIRE) -- Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, today announced that it has held a positive pre-New Drug...

Nicox gains expanded North American rights for Sjo(TM) from Immco Diagnostics

Nicox gains expanded North American rights for Sjö(TM) from Immco Diagnostics Nicox acquires extension of rights to market Sjö(TM) to all healthcare practitioners in North...

Nicox focuses US operations on national launches of Sjo(TM) and RetnaGene(TM) and restructures RPS(R) licensing agreement

Nicox to focus US marketing resources on national roll-out of Sjö(TM) and launch of RetnaGene(TM) Rapid Pathogen Screening (RPS®) partnership for AdenoPlus® and two other...

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

가장 활성
% 상승자
% 패자

기호	가격	볼륨
AAMAA Mission Acquisition Corp	US$ 10.0598 (0.00%)	0
AACT.UAres Acquisition Corporation II	US$ 10.91 (0.00%)	0
AACTAres Acquisition Corporation II	US$ 10.87 (0.00%)	0
AAAlcoa Corporation	US$ 40.95 (0.00%)	0
AAgilent Technologies	US$ 133.67 (0.00%)	0
AAMAA Mission Acquisition Corp	US$ 10.0598 (0.00%)	0
AACT.UAres Acquisition Corporation II	US$ 10.91 (0.00%)	0
AACTAres Acquisition Corporation II	US$ 10.87 (0.00%)	0
AAAlcoa Corporation	US$ 40.95 (0.00%)	0
AAgilent Technologies	US$ 133.67 (0.00%)	0
AAMAA Mission Acquisition Corp	US$ 10.0598 (0.00%)	0
AACT.UAres Acquisition Corporation II	US$ 10.91 (0.00%)	0
AACTAres Acquisition Corporation II	US$ 10.87 (0.00%)	0
AAAlcoa Corporation	US$ 40.95 (0.00%)	0
AAgilent Technologies	US$ 133.67 (0.00%)	0

게시물을 찾을 수 없습니다

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Cox Comm CL A SC23 (COX)

개인 투자자를 위한 전문가급 도구.

주요 통계 및 세부정보

COX 최신 뉴스

Nicox first quarter 2015 financial and business update

Nicox 2014 Financial Results and Business Update

Nicox receives Orphan Drug Designation from FDA for naproxcinod in Duchenne Muscular Dystrophy

Nicox signs exclusive license agreement with InSite Vision for AzaSite(R) and BromSite(TM) in Europe

Nicox holds successful pre-NDA meeting with FDA on AC-170 clinical package

Nicox gains expanded North American rights for Sjo(TM) from Immco Diagnostics

Nicox focuses US operations on national launches of Sjo(TM) and RetnaGene(TM) and restructures RPS(R) licensing agreement

Nicox to acquire Aciex Therapeutics, Inc.

Nicox launches commercial operations in Germany

Nicox and Sequenom announce the launch of expanded access to RetnaGene(TM) test portfolio in the U.S.

이동자

토론

최근 히스토리

회사 소개

사업

Popular

앱 받기

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Cox Comm CL A SC23 (COX) 시세

Cox Comm CL A SC23 (COX)

개인 투자자를 위한 전문가급 도구.

주요 통계 및 세부정보

COX 최신 뉴스

이동자

토론

최근 히스토리

회사 소개

사업

Popular

앱 받기

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE